Identification of the HIV-1 gp41 core-binding motif – HXXNPF  by Huang, Jing-He et al.
FEBS Letters 580 (2006) 4807–4814Identiﬁcation of the HIV-1 gp41 core-binding motif – HXXNPF
Jing-He Huanga, Zu-Qiang Liua, Shuwen Liub, Shibo Jiangb,c,*, Ying-Hua Chena,*
a Laboratory of Immunology, Department of Biology, Tsinghua University, Protein Science Laboratory of the Ministry of Education,
Beijing 100084, PR China
b Antiviral Research Center, Southern Medical University, Guangzhou 510515, PR China
c Laboratory of Viral Immunology, Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10021, USA
Received 23 May 2006; revised 10 July 2006; accepted 18 July 2006
Available online 4 August 2006
Edited by Hans-Dieter KlenkAbstract The HIV-1 gp41 core, a six-helix bundle formed be-
tween the N- and C-terminal heptad repeats, plays a critical role
in fusion between the viral and target cell membranes. Using
N36(L8)C34 as a model of the gp41 core to screen phage display
peptide libraries, we identiﬁed a common motif, HXXNPF (X is
any of the 20 natural amino acid residues). A selected positive
phage clone L7.8 speciﬁcally bound to N36(L8)C34 and this
binding could be blocked by a gp41 core-speciﬁc monoclonal
antibody (NC-1). JCH-4, a peptide containing HXXNPF motif,
eﬀectively inhibited HIV-1 envelope glycoprotein-mediated syn-
cytium-formation. The epitope of JCH-4 was proven to be linear
and might locate in the NHR regions of the gp41 core. These
data suggest that HXXNPF motif may be a gp41 core-binding
sequence and HXXNPF motif-containing molecules can be used
as probes for studying the role of the HIV-1 gp41 core in mem-
brane fusion process.
 2006 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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The human immunodeﬁciency virus type 1 (HIV-1) envelope
glycoprotein (Env) transmembrane subunit gp41 is an impor-
tant modulator in HIV-1 entry into its host cell. After the
Env surface subunit gp120 binds to the CD4 molecule [1]
and then to a chemokine coreceptor, CXCR4 or CCR5, on
the target cell [2], gp41 undergoes a multi-step structural tran-
sition [3]. Firstly, the fusion peptide, a stretch of hydrophobic
residues located at the N-terminus of gp41, is essential for
membrane fusion [4]. Subsequently, the N- and C-terminal
heptad repeat (NHR and CHR, respectively) regions associate
to form a six-helix bundle (also known as trimer-of-heterodi-
mers or trimer-of-hairpins), in which three NHR helices form
the central trimeric coiled-coil domain and three CHR helices
pack obliquely in an anti-parallel conﬁguration into the highly
conserved hydrophobic grooves on the surface of the central
coiled-coil [5,6]. Formation of the six-helix bundle brings the*Corresponding authors. Fax: +1 212 570 3099 (S. Jiang), +86 10
62771613 (Y.-H. Chen).
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doi:10.1016/j.febslet.2006.07.067viral and target cell membranes into proximity for facilitating
their merging.
Peptide derived from the gp41 NHR region (designated N-
peptides), including DP-107 [7], N51, N36, N34 [8–10], and
CHR region (named C-peptides), such as SJ-2176 [11], DP-
178 (also known as T-20) [12], C43, C34, and C28 [8–10],
has inhibitory activity against HIV-1 Env-mediated membrane
fusion by competing with the corresponding heptad-repeat
regions of the viral gp41, in a dominant-negative manner,
thereby preventing formation of the gp41 core. Mixing of the
N-peptides (e.g., N36 and N34) with the C-peptides (e.g.,
C34 and C28) results in formation of stable six-helix bundle
[9,10]. Similarly, the single-chain polypeptide N34(L6)C28 in
which the N34 C-terminus is connected to the C28 N-terminus
by a six-amino acid linker Ser-Gly-Gly-Arg-Gly-Gly can also
form a six-helix bundle [10]. Therefore, this polypeptide can
be used as a model of the gp41 core for studying the mecha-
nism of gp41.
All the accumulated evidences suggest that formation of the
six-helix bundle is a critical step for gp41-mediated membrane
fusion [3,5,6,8–10,13–25].However, it is unclearwhether the for-
mation of the six-helix bundle needs assistance of a protein or
other components in the lipid membrane of the target cells since
high energy is required to make the helices bend to form hairpin
structure and to pull the viral and cellular membranes into prox-
imity. It is also unknown whether the formed six-helix bundle
has any function in the late stages of the HIV-1 fusion events.
Shu et al. [18] have demonstrated that the gp41 core can interact
with the lipids in cellularmembranes. It has been speculated that
gp41 core may participate in the fusion pore formation, but no
valid evidence has been provided. Therefore, it is important to
identify a probe that can interact with the gp41 core.
Screening of phage-displayed libraries is a powerful tech-
nique for identifying the ligand binding to the target protein
[26]. In the present study, we screened two phage-displayed li-
braries using a polypeptide N36(L8)C34 as a model of the
gp41 core. We identiﬁed a consensus motif HXXNPF (X is
any of the 20 natural amino acid residues) that could inhibit
HIV-1 envelope glycoprotein-mediated syncytium-formation
and characterized its interaction with the gp41.2. Materials and methods
2.1. Cell lines
3T3 cells stably transduced with MLVMX-CD4 and MX-CXCR4
vectors (3T3.T4.CXCR4) were cultured in DMEMcomplementedmed-
ium with 10% FBS, 100 IU/ml penicillin and 100 IU/ml streptomycinblished by Elsevier B.V. All rights reserved.
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1HXB2 Env expressing vector pEE14 (CHO-WT) or control pEE14 vec-
tor (CHO-EE) were cultured in Glutamine-deﬁcient minimal essential
medium (GMEM-S) containing 400 lM methionine sulfoximine (Sig-
ma, St. Louis, MO).
2.2. Expression and puriﬁcation of N36(L8)C34
For expression of N36(L8)C34, the gene fragments coding for N36
(spanning residues 546–581 in gp41) and C34 (spanning 628–661
in gp41) were PCR-ampliﬁed, respectively, from the corresponding
plasmid coding gp160 with the primers. Primers F1/R1 (F1: 5 0-
gcgcggatcctctggtatagtgcagcag-30, R1: 5 0-ccaagcttgccaccccccag-
gattcttgcctg-30) were used to amplify the N36 fragment while the
primers F2/R2 (F2: 5 0-gcaagcttggtggcgggtggatggagtgggac-30, R2: 5 0-
gcctcgagtcacaataattcttgttcattc-3 0) were used to amplify the C34 frag-
ment. 100 ng of each product were mixed together and used as
templates for overlap extension PCR using primers F1/R2. The C-ter-
minus of N36 was connected to the N-terminus of C34 by the hydro-
philic linker Gly-Gly-Gly-Arg-Leu-Gly-Gly-Gly (L8). The fragments
were cloned into the expression plasmid pET28a via their BamHI and
XhoI restriction sites, and the protein was overproduced in Escherichia
coli BL21(DE3)/pLysS. The protein in the supernatants was puriﬁed by
immobilized metal-aﬃnity chromatography on a Ni-NTA column (elu-
tion with 250 mM imidazole). After dialyzing with PBS, pH7.2, the
puriﬁed recombinant protein was analyzed by SDS–PAGE.
2.3. Circular dichroism spectroscopy
The puriﬁed polypeptide N36(L8)C34 and the control peptide
N34(L6)C28 kindly provided by Dr. Min Lu at the Weill Medical Col-
lege of Cornell University were dissolved at 20 lM in PBS (pH 7.2).
Circular dichroism (CD) spectra of these polypeptides were obtained
using an Aviv 202 spectropolarimeter by averaging three measure-
ments. Spectra were scanned in a capped quartz optical cell with a
1 mm path length, at 25 C.
2.4. Screening of phage display peptides
Peroxidase-conjugated anti-M13 phage antibody was purchased
from Amersham Pharmacia Biotech (Piscataway, NJ). Ph.D.-7 and
Ph.D.-12 phage display peptide libraries were obtained from New Eng-
land Biolabs (Beverly, MA). Biopanning was performed following the
manufacturer’s standard procedure. The polypeptide N36(L8)C34 was
used to coat microtiter plates at 10 lg/ml. After three rounds of selec-
tion, the bound phages were eluted with Glycine-HCl buﬀer (pH 2.2).
The selected clones were added to E. coli (strain ER2738) culture
(1:100) for infection at 37 C for 5 h with shaking. The culture super-
natants containing phage particles were harvested as phage stocks and
stored at 20 C until use.
2.5. Enzyme-linked immunosorbent assay
To determine the activity of the phage clones binding to the gp41
core modeled by the polypeptide N36(L8)C34, wells of microplates
were coated with 50 ll of N36(L8)C34 (0.5 lg/ml) or the mixture of
the peptides N36 (4 lM) and C34 (4 lM) in 0.1 M NaHCO3 buﬀer
(pH 8.6) overnight. The coated wells were blocked with Tris buﬀer
solution (TBS, pH 7.5) containing 0.25% gelatin (additional uncoated
control wells were blocked with TBS containing 0.25% gelatin in order
to exclude the selected clones that bind gelatin-coated plastic).
After three washes with TBS containing 0.1% Tween-20 (TBS-T),
phages diluted in TBS at series of 5-fold dilutions (starting from
1011 particles/ml) were added to the wells, followed by incubation at
room temperature for 1.5 h with agitation. After extensive washes, the
amount of bound phage was detected by addition of peroxidase-conju-
gated anti-M13 phage antibody and substrate, o-phenylenediamine
(OPD), sequentially. The absorbance at 450 nm (A450) was recorded.
For binding competition assay, wells of microplates were coated
with 50 ll of N36(L8)C34 (1 lM) and blocked with blocking buﬀer
(PBS containing 1% non-fat dry milk). N36(L8)C34 or the control pep-
tide C34 at four serial dilutions in PBS (starting form 4 lM) was added
and incubated with phage (5 · 1010 particles/ml) for 1 h in 37 C in the
micro-tube before they were added into the wells. After extensive
washes, the amount of bound phage was detected as described above.
To test if NC-1 could compete with the phage to bind the six-helix
bundle, wells of microplates were coated with 50 ll of N36(L8)C34
(1 lg/ml). After blocking and washes, 50 ll of the mAb NC-1 or anunrelated (anti-heamagglutinin) mAb at 4-fold serial dilutions in
TBS-T was added and incubated at room temperature for 1 h, followed
by addition of a selected phage clone or M13 phages (5 · 1010 particles/
ml). After incubation at room temperature for 1.5 h with agitation and
extensive washes, the amount of bound phage was detected as de-
scribed above.
2.6. DNA sequencing
The positive phage clones were precipitated with polyethylene gly-
col. The DNA samples were prepared by phenol extraction and the
DNA sequences were determined using primer provided in the Ph.D.
kit (BioLabs).
2.7. Western blot analysis
N36(L8)C34 was electrophoresed by SDS–PAGE and transferred
onto a nitrocellulose membrane. All subsequent steps were carried
out at room temperature. The nitrocellulose membrane was blocked
with a blocking buﬀer (TBS containing 2% non-fat dry milk) at room
temperature for 1 h and was cut into strips. The strips were then incu-
bated in TBST containing phage clone L7.8 or M13 (1010 particles/ml)
at room temperature for 2 h. After extensive washes, the strips were
incubated with peroxidase-conjugated anti-M13 phage antibody or
peroxidase-conjugated rabbit anti-mouse IgG, followed by incubation
with the substrate, 3,3 0-diaminobenzidine (DAB) (Amresco, OH,
USA), sequentially.
2.8. The binding activity of N36, C34, and N36(L8)C34 to JCH-4
A biotinylated JCH-4 peptide, corresponding to the HXXNPF
motif-containing sequence of phage clone L7.8 was synthesized (Table
3). To determine the binding activity of this peptide to the gp41 core,
N36, and C34, wells of microplates were coated with 50 ll of JCH-4
(5 lM). After blocking and washes, 50 ll of N36, C34, or
N36(L8)C34 at 4-fold serial dilutions (starting from 5 lM) in PBS
was added. After incubation at room temperature for 1.5 h with agita-
tion and extensive washes, the amount of bound N36, C34, or
N36(L8)C34 was detected by addition of rabbit anti-N36/C34 poly-
clonal antibodies and peroxidase-conjugated anti-rabbit IgG and sub-
strate OPD, sequentially. The absorbance at 450 nm (A450) was
recorded.
2.9. HIV-1 Env-mediated syncytium-formation assay
Target (3T3.T4.CXCR4) cells (5 · 104) resuspended in DMEM con-
taining 10% FBS were plated in 96-well plates and incubated overnight
at 37 C, followed by washes with GMEM-S medium. Then, 2 · 104
eﬀector (CHO-WT) cells pre-stimulated with 7 mM sodium butyrate
for about 20 h were added in the absence or presence of an inhibitor
at granted concentration. After co-cultured for 24 h at 37 C, the syn-
cytia, deﬁned as giant cells with diameters more than four times bigger
than those of single cells, were counted under a microscope. The per-
centage of inhibition of syncytium-formation was calculated using the
formula: % inhibition = [1  (number of syncytia in a well containing
an inhibitor)/number of syncytia in a well containing no inhibi-
tor] · 100. To determine the biological function of JCH-4, JCH-4 pep-
tide (starting from 200 lg/ml) were pre-incubated with CHO-WT cells
at 37 C for 60 min, followed by addition of the mixture to the target
cells. Other steps were the same as above. The concentration for 50%
inhibition (IC50) was calculated using the software Calcusyn [27].3. Results
3.1. Expression, puriﬁcation and characterization of
N36(L8)C34
It was previously demonstrated that the polypeptide
N34(L6)C28 could form trimer of heterodimers [10], represent-
ing the gp41 core structure. In the present study, we con-
structed a similar polypeptide, designated N36(L8)C34, in
which the C-terminus of N36 is connected to the N-terminus
of C34 by the hydrophilic linker Gly-Gly-Gly-Arg-Leu-Gly-
Gly-Gly (L8). N36(L8)C34 was expressed in E. coli BL21
(DE3)/pLysS by using the T7 expression system. Proteins were
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matography on a Ni-NTA column. Protein identity was con-
ﬁrmed by mass spectrometry. As analyzed by SDS–PAGE,
the puriﬁed N36(L8)C34 exhibited a single band with a mole-
cular weight of about 11.5 kDa, corresponding to predicted
molecular weight of N36(L8)C34 (Fig. 1A). In Western blot
using rabbit antibodies directed against the N36 and C34 mix-
ture, two bands were revealed. The major band at the lower
position corresponded to the single chain of N36(L8)C34 with
a molecular weight of about 11.5 kDa, while the minor band at
the upper position had a molecular weight of about 34.5 kDa,
suggesting that a small part of the N36(L8)C34 polypeptide
retains in trimeric form under the electrophoresis condition
(Fig. 1B). Using a mAb NC-1 that is speciﬁc for the gp41
six-helix bundle core conformation [13] in a sandwich en-
zyme-linked immunosorbent assay (ELISA) [28], we found
that both N36(L8)C34 and N34(L6)C28 were reactive with
the mAb NC-1 in a dose-dependent manner (Fig. 2A). The sec-
ondary structure of the N36(L8)C34 was determined by circu-
lar dichroism spectra. As shown in Fig. 2B, like N34(L6)C28,
N36(L8)C34 exhibited typical a-helical structure in PBS solu-
tions. These results conﬁrm that N36(L8)C34 forms six-helix
bundle in solution.
3.2. Selection of N36(L8)C34-binding phage clones
We used N36(L8)C34 to screen the 7-mer and 12-mer pep-
tide libraries. The elution of phage was titered using IPTG/
Xgal plate after biopanning. After three rounds of biopanning,
the phages that bound N36(L8)C34 were enriched 100–1000
folds (Table 1). We selected a number of positive clones which
bound signiﬁcantly to N36(L8)C34 in dose-dependent man-Fig. 1. Electrophoresis analysis of the puriﬁed N36(L8)C34. (A) SDS–
PAGE. N36(L8)C34 puriﬁed from the cell lysates by immobilized
metal-aﬃnity chromatography on a Ni-NTA column was analyzed in
SDS–PAGE. The low molecular weight (LMW) markers (Amersham
Pharmacia Biotech Inc.), consisting of phosphorylase b (97 kDa),
albumin (66 kDa), ovalbumin (45 kDa), carbonic anhydrase (30 kDa),
trypsin inhibitor (20.1 kDa), and a-lactalbumin (14.4 kDa) were
included for estimation of the polypeptide molecular weight. (B)
Western blot. Rabbit antibodies directed against the mixture of N36/
C34 were used to reveal the bands of monomeric (lower band) and
trimeric (upper band) N36(L8)C34 polypeptide.
Wavelength (nm)
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Fig. 2. Analysis of the conformation of N36(L8)C34. (A) ELISA. The
gp41 core-speciﬁc mAb NC-1 was used to identify the six-helix bundle
formed by the polypeptides N36(L8)C34 and N34(L6)C28. (B) CD
analysis. CD spectra of N36(L8)C34 and N34(L6)C28 were measured
using Aviv 202 spectropolarimeter.ners, while the control M13 bacteriophage and the blocking
agent gelatin showed no binding to N36(L8)C34 (Fig. 3A
and B). This result suggests that the selected clones bind to
N36(L8)C34 via some speciﬁc peptide sequences displayed
on the phages.
3.3. Identiﬁcation of the HXXNPF motif in the selected phage
clones that may be responsible for binding to N36(L8)C34
In order to identify the residues responsible for binding
to the six-helix bundle of the gp41 core, we analyzed the
sequences of selected clones with high N36(L8)C34-binding
aﬃnity and performed a multiple alignment analysis. Among
the twenty-seven 7-mer phage clones and eleven 12-mer phage
clones sequenced, twenty-three 7-mer and seven 12-mer phages
clones, respectively, were found to contain a common motif,
HXXNPF (X represents any of the 20 natural amino acid res-
idues). One 7-mer and two 12-mer phages clones, respectively,
contained the HXXDPF motif (Table 2). The predominant se-
quences were HMQNPF and HMSNPF. This result suggests
that the HXXNPF and HXXDPF motifs may be responsible
for the binding of the phage clones to N36(L8)C34.
Table 1
Enrichment of the gp41 core-binding phages
Biopanning 7-mer peptide library 12-mer peptide library
Output/input Enriched (fold) Output/input Enriched (fold)
The 1st round 3.33 · 105/2 · 1011 1 2.74 · 107/2 · 1011 1
The 2nd round 1.02 · 106/2 · 1011 4 4.46 · 108/2 · 1011 16
The 3rd round 5.06 · 107/2 · 1011 150 8.51 · 109/5 · 1010 1000
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Fig. 3. Binding of the selected phage clones to N36(L8)C34. The
binding was detected by ELISA with a peroxidase-conjugated anti-
M13 antibody as described in the text. M13 phage particles and gelatin
(a blocking agent used in this assay) were included as negative controls.
The positive phage clones were selected from the 7-mer (A) and the 12-
mer (B) phage display peptide libraries.
Table 2
Amino acid sequences of the peptides expressed in the gp41 core-
binding phage clones selected from the 7-mer and 12-mer phage
peptide libraries
Motifs selected from the
7-mer peptide library
Motifs selected from the 12-mer
peptide library
Frequency Amino acid
sequence of
the insert
Frequency Amino acid
sequence of
the insert
7 K H M Q N P F 1 N H L H N P F T V D S G
3 G H M S N P F 1 S H L H N P F A F P A Q
2 S H L A N P F 1 D H T T N P F G T P L P
2 S H L S N P F 1 S H T E N P F T V P Q Q
1 D H L R N P F 1 F H L D N P F L A D R S
1 F H Q P N P F 1 A H T T D P F Q P W A L
1 L H L R N P F 1 S H L S D P F G E L R P
1 K H L I N P F 1 G H N Q F N P F T F V M
1 Q H L Q N P F 1 G H N H V L N P F K V Y
1 S H N P N P F
1 T H L T N P F
1 Q H L L N P F
1 W H N S N P F
1 K H L S D P F
Consensus motif: HXXNPF (highlighted in bold and italic).
Table 3
Amino acid sequences of the peptide JCH-4
SHSQHLLNPFGGC
Note: the shared sequence is highlighted in italic and the HXXNPF
motif is marked in bold and italic.
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To determine the binding speciﬁcity of the phage clones con-
taining the HXXNPF motif, a positive clone with high binding
activity, L7.8 (Fig. 3A), was selected for testing its binding
ability to N36(L8)C34. The M13 phage, which does not ex-
press the HXXNPF-containing peptides, was used as a con-
trol. As shown in Fig. 4A, the phage clone L7.8 strongly
bound to N36(L8)C34 in a dose-dependent fashion. The phage
clone L7.8 also bound to the complex formed by mixing the
peptides N36 and C34 (Fig. 4B), excluding the possibility of
the phages binding to the linker L8. M13 showed no bind-
ing activity to any of the molecules (Fig. 4A and B). In thecompetition ELISA, N36(L8)C34 in solution blocked the bind-
ing of phage clone L7.8 to the immobilized N36(L8)C34
(Fig. 4C). MAb NC-1, which can speciﬁcally recognize the
gp41 core structure, blocked binding of the phage clone L7.8
to N36(L8)C34 in a dose-dependent manner (IC50 = 6.351 ±
0.281 lg/ml), whereas the unrelated (anti-heamagglutinin)
mAb showed no inhibitory activity (Fig. 4D). These data sug-
gest that the phage clones expressing the HXXNPF motif may
have common binding sites on the six-helix bundle of the gp41
core with NC-1.
The binding site of NC-1 is found to be a discontinuous epi-
tope on six-helix bundle [13]. To determine whether the bind-
ing site of phage clone L7.8 on N36(L8)C34 was a linear
epitope or a conformational epitope, phage clone L7.8 was
probed by a reduced western blot analysis against
N36(L8)C34. M13 was used as a negative control. As shown
in Fig. 4E, phage clone L7.8 bound to the N36(L8)C34 (lane
1), whereas M13 showed no binding activity to N36(L8)C34
(lane 2). These data suggest that the epitope of the HXXNPF
motif on the six-helix bundle is linear but not conformational.
HXXNPF motif-containing molecules may partly overlap the
binding site of mAb NC-1 on the gp41 core structure.
00.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
0 640 160 40 10
Reciprocal dilution of the phage
Bi
nd
in
g 
to
 N
36
/C
34
 c
om
pl
ex
 (A
45
0)
L7.8
M13
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1250 250 50 10
Reciprocal dilution of the phage
Bi
nd
in
g 
to
 N
36
(L8
)C
34
 (A
45
0)
L7.8
M13
0
0.1
0.2
0.3
0.4
0.5
0.6
0.003 0.013 0.052 0.208
Concentration of  peptides (µM)
Bi
nd
in
g 
 to
 N
36
(L8
)C
34
 (A
45
0)
N36(L8)C34
C34
A
D
E
B
C
0
10
20
30
40
50
60
70
80
90
0 0.0387 0.156 0.625 2.5 10 40
mAb concentration (µg/ml)
%
 In
hi
bi
tio
n 
of
 b
in
di
ng
 to
 N
36
(L8
)C
34
L7.8 + NC-1 mAb
L7.8 + control mAb
1    2   
N36(L8)C34
97kD
30kD
20.1kD
14.4kD
45kD
66kD
Fig. 4. Binding speciﬁcity of the selected phage clone L7.8. An ELISA was performed to determine the binding activity of the phage clone L7.8 to
N36(L8)C34 (A) and the complex formed by mixing the peptides N36 and C34 (B). Phage M13 was used as a control. (C) The inhibitory activity of
the N36(L8)C34 in solution on the phage clone L7.8 binding to the immobilized N36(L8)C34. C34 was included as a negative control. (D) The
inhibitory activity of the mAb NC-1 on the phage clone L7.8 binding to N36(L8)C34. An unrelated (anti-heamagglutinin) mAb was included as a
negative control. (E) Western blot analysis of phage clone L7.8 (lane 1) binding to N36(L8)C34. M13 (lane 2) was used as a negative control. The
MW of N36(L8)C34 was about 11.5 kDa.
J.-H. Huang et al. / FEBS Letters 580 (2006) 4807–4814 48113.5. Synthesis and characterization of the HXXNPF motif-
containing peptide JCH-4
To further determine the role of HXXNPF motif in the L7.8
phage clone, we synthesized a short peptide derived from the
HXXNPF motif containing fragment (JCH-4) and tested its
activity. The gp41 core could eﬀectively bind to this 13-mer
peptide in a dose-dependent manner (Fig. 5A), whereas itshowed no binding activity to the blocking agent milk. The
binding of JCH-4 to the separate N36 and C34 peptides side
by side against N36(L8)C34 were also shown (Fig. 5B).
JCH-4 bound to N36 with the same intensity as it bound to
N36(L8)C34. However, it showed no binding ability to C34.
These results suggest that unlike NC-1, which speciﬁcally rec-
ognizes the discontinuous epitope on the complexes formed by
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Fig. 5. Characterization of the peptide JCH-4. An ELISA was
performed to determine the binding activity of the N36(L8)C34 to
JCH-4 (A). The binding of JCH-4 to the separate N36 and C34
peptides side by side against N36(L8)C34 (B).
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NHR regions of gp41 core, and the epitope is linear.
Then we investigated whether the peptide JCH-4 could inhi-
bit HIV-1 Env-mediated syncytium-formation. The co-culture
of 3T3.T4.CXCR4 cells and CHO-EE control cells displayed a
normal density and morphology (Fig. 6A). Twenty-four hours
after 3T3.T4.CXCR4 co-cultured with CHO-WT cells express-
ing HIV-1 Env, signiﬁcant amount of syncytia appeared
(Fig. 6B). When 200 lg/ml of the peptide JCH-4 was added
to the target cells before addition of 3T3.T4.CXCR4 cells, nei-
ther syncytium-formation nor cytotoxicity was observed
(Fig. 6C). JCH-4 inhibited syncytium-formation in a dose-
dependent manner (IC50 = 9.121 ± 1.980 lg/ml) (Fig. 6D).
These results conﬁrm that the HXXNPF motif in the phage
clone L7.8 is responsible for binding to the gp41 core and
inhibiting HIV-1 fusion.
Fig. 6. Inhibition of HIV-1 Env-mediated syncytium-formation by
JCH-4. (A) Negative control: 3T3.T4.CXCR4 cells + CHO-EE cells.
(B) Positive control: 3T3.T4.CXCR4 cells + CHO-WT cells which
express HIV-1 Env. (C) 3T3.T4.CXCR4 cells + JCH-4 (200 lg/
ml) + CHO-WT cells. (D) JCH-4 inhibited HIV-1 Env-mediated
syncytium-formation in a dose-dependent manner. Error bars repre-
sent the standard errors of means obtained from at least two
independent measurements for each concentration.4. Discussion
Entry of HIV-1 into a target cell is initiated by binding of the
Env surface subunit gp120 to cellular receptor CD4 [1] and a
chemokine coreceptor, CXCR4 or CCR5 [2], followed by a
J.-H. Huang et al. / FEBS Letters 580 (2006) 4807–4814 4813series of conformational changes of the Env transmembrane
subunit gp41 to form a six-helix bundle, bringing the viral
and target cell membranes into proximity [3,5,6,8]. However,
the events prior to the fusion-pore formation and after the
gp41 core formation have not been deﬁned. Accumulated evi-
dences suggest that the six-helix bundle of the gp41 core may
participate in the formation of the fusion pore through direct
protein–membrane interactions [18–21]. But it is unclear
whether the gp41 core directly interacts with the lipids in the
cellular membrane or binds to a membrane protein prior to
its interaction with the membrane lipids.
Using the single-chain polypeptide N36(L8)C34 as an
in vitro model of the gp41 six-helix bundle to screen for the
gp41 core-binding motif(s) from the 7-mer and 12-mer peptide
libraries displayed on the bacteriophage M13. We identiﬁed a
consensus motif HXXNPF that could bind to the core of gp41
and inhibit HIV-1 gp41-mediated syncytium-formation.
NC-1, a monoclonal antibody that speciﬁcally recognizes the
gp41 core conformation, could compete with the HXXNPF
motif to bind N36(L8)C34 in a dose-dependent manner. How-
ever, the characters of NC-1 and the HXXNPF motif were
proved to be diﬀerent. (1) The binding sites of NC-1 and the
HXXNPF motif on the six-helix bundle were diﬀerent. JCH-4
speciﬁcally recognized the linear epitope in the NHR regions
of gp41 core, while the epitope of NC-1 was discontinuous
and formed by the NHR and CHR regions. We speculated that
the binding site of HXXNPF motif-containing molecule might
partly overlap the binding site of mAb NC-1 on the gp41 core
structure, so that NC-1 could block the binding of HXXNPF
motif to gp41 core. (2) Although the mAb NC-1 binds to the
gp41 core presented on the HIV-1 infected or Env-expressed
cells after triggered byCD4 [13,23,24], it has nodetectable inhib-
itory activity on HIV-1 Env-mediated syncytium-formation.
However, the synthetic peptide JCH-4 could inhibit the HIV-1
envelope glycoprotein-mediated syncytium-formation. One
explanation is that NC-1 with a molecular size of 145 kDa
may not approach the six-helix bundle. It is possible that the
six-helix bundle is located in a narrow space between the viral
and the target cell membranes, which may be inaccessible to
the NC-1 due to the steric hindrance eﬀect. The supporting evi-
dence is as follows: (i) Previous reports found that the HIV-1
neutralizing activity of the X5 scFv was dramatically reduced
upon conversion to an IgG presumably because the larger IgG
could not gain access to its binding site [29]. (ii) The steric acces-
sibility of the HIV-1 gp41 N-trimer region showed that the C-
peptide inhibitor progressively lost inhibitory potency when it
was attached to an increasing size of cargo protein [30]. In our
study, JCH-4, a protein fragment with a molecular size much
smaller thanNC-1may be able to access andbind to the six-helix
bundle during the stages of membrane fusion.
JCH-4 recognizes the epitope in the NHR regions of gp41
core may shed light on the mechanism that how HXXNPF
motif inhibits the gp41-mediated syncytium-formation. Deep
hydrophobic cavities within the internal trimeric NHR were
identiﬁed and proven to play an important role in the interac-
tion between the NHR and CHR regions and in the gp41-med-
iated membrane fusion [5,31]. The deep cavity is an ideal target
for small molecular inhibitors, as it appears that the virus is
relative slow in developing resistance to these inhibitors. Short
cyclic peptides consisting of D-amino acids that targeted to the
deep hydrophobic cavity have inhibitory activity against HIV-1 mediated membrane fusion [32]. Based on the binding data,
we hypothesize that HXXNPF motif may inhibit fusion by
binding to the NHR regions of gp41 core, but the precise bind-
ing site still remains to be elucidated.
We speculate that the gp41 core may bind to some cellular
proteins to execute its function in the late stage of membrane
fusion. We previously demonstrated that the HIV-1 gp41
bound through its N- or C-terminal domains to some proteins
with molecular weight of 45 and 62 kDa (P45 and P62, respec-
tively) on the T and B lymphocytes and monocytes [33,34]. But
these gp41-binding proteins have not been fully characterized
due to the diﬃculty of puriﬁcation and sequencing of these
membrane proteins. Speth et al. [35] reported that a 60 kDa
heat-shock protein-like molecule interacts with the HIV-1
gp41. Bristow et al. [36] have demonstrated that human leuko-
cyte elastase (HLE) interacts with the HIV-1 gp41 and the
natural HLE ligand a1-proteinase inhibitor (a1-antitrypsin,
a1-PI) interferes with the HIV-1 infectivity. Recently, Hovanc-
essin et al. [37] have shown that gp41 binds to a cellular scaf-
folding protein, caveolin-1, which organizes and concentrates
speciﬁc ligands within the glycolipid-enriched membrane
microdomains, known as lipid rafts. In our study, the
HXXNPF motif was able to bind the core of gp41 and inhibit
the gp41-mediated cell–cell fusion. These data suggest that
HXXNPF motif-containing molecules (proteins or peptides)
may speciﬁcally bind to the HIV-1 gp41 core structure by a
mechanism that remains to be elucidated. We have found a
XXNPF motif-containing protein that speciﬁcally interacted
with the gp41 core, but we still need more data for veriﬁcation.
To sum up, a gp41 core-binding sequence HXXNPF motif was
found and the HXXNPF motif-containing molecules could be
used as probes for studying the role of the HIV-1 gp41 core in
the stage of membrane fusion process.
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